InflaRx (NASDAQ:IFRX) Given New $6.00 Price Target at Cantor Fitzgerald

InflaRx (NASDAQ:IFRX) had its price target boosted by Cantor Fitzgerald from $4.00 to $6.00 in a report issued on Friday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.

Other equities analysts have also recently issued reports about the company. Raymond James Financial upgraded InflaRx from an “outperform” rating to a “strong-buy” rating and raised their price objective for the stock from $7.00 to $9.00 in a research note on Wednesday, May 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, June 24th. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Zacks Research upgraded InflaRx from a “hold” rating to a “strong-buy” rating in a report on Monday, July 27th. Finally, Guggenheim reissued a “buy” rating and set a $14.00 price target on shares of InflaRx in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

InflaRx Trading Up 7.0%

InflaRx stock opened at $1.84 on Friday. InflaRx has a 52 week low of $0.78 and a 52 week high of $2.95. The stock has a 50-day moving average price of $1.89 and a 200 day moving average price of $1.53. The stock has a market cap of $133.01 million, a PE ratio of -3.17 and a beta of 2.48.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.04). On average, equities analysts predict that InflaRx will post -0.29 EPS for the current year.

Institutional Trading of InflaRx

Several hedge funds have recently modified their holdings of IFRX. Cubist Systematic Strategies LLC raised its position in InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after purchasing an additional 7,616 shares during the last quarter. HRT Financial LP acquired a new stake in InflaRx in the fourth quarter worth about $47,000. Concurrent Investment Advisors LLC increased its position in InflaRx by 56.9% in the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock worth $53,000 after purchasing an additional 19,200 shares during the period. Insigneo Advisory Services LLC bought a new stake in InflaRx during the 4th quarter worth about $61,000. Finally, Quadrature Capital Ltd bought a new stake in InflaRx during the 4th quarter worth about $104,000. 42.39% of the stock is owned by institutional investors.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.